Core 1: Pre-clinical Modeling Core
核心 1:临床前建模核心
基本信息
- 批准号:10259874
- 负责人:
- 金额:$ 31.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-20 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAnimal ModelAnimalsBackBig DataBioinformaticsBiological MarkersBiological ModelsBloodBlood CellsBone Marrow TransplantationCellsClinicalCore FacilityDataData AnalysesEngineeringFutureGene ProteinsGenerationsGeneticGerm-FreeGnotobioticGoalsHumanImiquimodImmune responseIn VitroInflammationInflammatoryKnock-outKnockout MiceLinkMediatingMediator of activation proteinMethodologyModelingModificationMolecularMolecular GeneticsMouse StrainsMusPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPre-Clinical ModelPreclinical TestingPsoriasisResearchResearch Project GrantsResourcesRoleSamplingSkinStructureSystemTechnologyTestingTissuesTransgenic OrganismsTranslatingTranslational ResearchTransplantationValidationXenograft procedurebacteriomebaseclinical applicationclinical careclinical translationcohortcomorbiditydrug repurposingdrug testingefficacy testingexperimental studyflexibilitygenetic approachgenetic manipulationin vivoinnovationinsightinterleukin-17Cinterleukin-23meetingsmetabolomicsmicrobialmouse modelmycobiomenovelpre-clinicalpreclinical evaluationreconstitutionskin lesionskin xenograftsuccesstooltranscriptomicstreatment response
项目摘要
The CORT Preclinical Modeling Core (PMC) will serve as a resource for the Collaborative Research
Project (CRP), providing enabling technology and model systems that will be used to specifically test targets
identified by the Applied Meta-Omics Core (AMC). The broad goal of the CWRU CORT is to combine new
bioinformatic methodologies with advanced murine and human experimental approaches to translate
scientific findings into clinical applications that more nimbly advance therapy for psoriasis and related
inflammatory comorbidities. This goal requires a rich array of readily-deployable and flexible/adaptable
psoriasis-relevant and innovative in vivo systems that permit testing of a wide range of novel concepts, roles of
specific mediator/pathways, and efficacies of specific repurposed and anti-psoriasis drugs. The PMC will meet
this need, by working closely with the AMC and CRP to provide all needed transgenic and psoriasiform mouse
models and isolated tissues, blood and cells for analyses and bioinformatic-derived biomarker and target
generation. The PMC will enable generation and testing by the CRP of hypotheses generated as a result of
human and mouse bioinformatics data. The goals of the PMC include providing enabling materials, technology
and expertise in psoriasis mouse models and mouse molecular genetics that will allow and enhance successful
completion of the CRP Aims and Objectives. To support the CRP’s objectives, the PMC will: A. Provide
genetically modified existing mouse models of psoriasiform skin inflammation; B. Engineer new innovative
genetic mouse models based upon novel genes/proteins identified by the AMC; C. Provide primary cells
isolated from genetically manipulated mice for ex vivo hypothesis testing; D. Identify the most appropriate
psoriasis mouse model(s) to test efficacy of pathway-specific drugs identified by the AMC, and generate and
provide mice to the CRP for preclinical testing and evaluation; and E. Generate germ-free mice and re-
introduce bacteriome/mycobiome species identified by the AMC and provide animals to the CRP for analysis
and hypothesis testing. The PMC will also provide reiterative data generation for additional “omics” data
analyses and identification by the AMC of novel pathways, biomarkers, micro/mycobiome species, and cellular
mediators, contributing new insight into psoriasis pathogenesis, enabling validation in clinical psoriasis patient
samples. The PMC provides a coordinated center of excellence enabling the creation of new, and utilization of
existing, animal models of psoriasis to better test the cellular and molecular mechanisms hypothesized to
mediate psoriasis. Within the novel CORT structure of highly interactive Cores synergistically interacting with
the central CRP, the PMC team's expertise, innovation and extensive resources will drive the CORT's
transforming and sustainable impact on psoriasis understanding and clinical care.
CORT临床前建模核心(PMC)将作为合作研究的资源
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicole Leanne Ward其他文献
Nicole Leanne Ward的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicole Leanne Ward', 18)}}的其他基金
Kallikrein-PAR interactions in skin inflammation
激肽释放酶-PAR 在皮肤炎症中的相互作用
- 批准号:
10208722 - 财政年份:2018
- 资助金额:
$ 31.41万 - 项目类别:
Kallikrein-PAR interactions in skin inflammation
激肽释放酶-PAR 在皮肤炎症中的相互作用
- 批准号:
10615327 - 财政年份:2018
- 资助金额:
$ 31.41万 - 项目类别:
Kallikrein-PAR interactions in skin inflammation
激肽释放酶-PAR 在皮肤炎症中的相互作用
- 批准号:
10449979 - 财政年份:2018
- 资助金额:
$ 31.41万 - 项目类别:
Project 1: Host Immune Response to Chronic Psoriasis Inflammation
项目 1:宿主对慢性银屑病炎症的免疫反应
- 批准号:
10259876 - 财政年份:2017
- 资助金额:
$ 31.41万 - 项目类别:
Project 1: Host Immune Response to Chronic Psoriasis Inflammation
项目 1:宿主对慢性银屑病炎症的免疫反应
- 批准号:
10005125 - 财政年份:2017
- 资助金额:
$ 31.41万 - 项目类别:
Neurogenic inflammation and psoriasiform dermatitis
神经源性炎症和牛皮癣样皮炎
- 批准号:
8706044 - 财政年份:2013
- 资助金额:
$ 31.41万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists